[
    [
        {
            "time": "",
            "original_text": "大南药增速疲软!子公司被列招采失信名单?白云山半年报老问题仍在 关联方问题",
            "features": {
                "keywords": [
                    "大南药",
                    "增速疲软",
                    "子公司",
                    "招采失信名单",
                    "白云山",
                    "半年报",
                    "关联方问题"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大南药增速疲软!子公司被列招采失信名单?白云山半年报老问题仍在 关联方问题",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]